Cisatracurium
A nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle relaxation for endotracheal intubation and mechanical ventilation. It undergoes Hofmann elimination, a spontaneous chemical degradation independent of liver or kidney function, making it particularly useful in patients with organ dysfunction. It has minimal histamine-releasing properties compared to atracurium.
Moleküler Ağırlık
929,1000 g/mol
LogP
7,90
TPSA
126,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC
InChI
InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
Molecular Formula
C53H72N2O12+2
HBD / HBA
- / 12
Döndürülebilir Bağlar
26
Ağır Atomlar
67
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle relaxation for endotracheal intubation and mechanical ventilation. It undergoes Hofmann elimination, a spontaneous chemical degradation independent of liver or kidney function, making it particularly useful in patients with organ dysfunction. It has minimal histamine-releasing properties compared to atracurium.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Cisatracurium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201248. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 62887. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cisatracurium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cisatracurium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cisatracurium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cisatracurium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cisatracurium"></drugfyi-drug>